Barry Labinger Joins Biothera Pharmaceutical
With nearly three decades of experience in the pharmaceutical and biotech industry, Barry Labinger was named as the Chief Executive Officer at Biothera. His experience in oncology drug development will offer a great contribution to the company’s focus—novel cancer immunotherapy. “Barry has the strong leadership and management skills to take Biothera Pharmaceutical forward and realize the full potential of Imprime PGG, the company’s first-in-class immune modulator, which we believe is the next step in immuno oncology,” said Richard G. Mueller, Chairman of the Board, Biothera Holding Corp.
Labinger previously served as Executive Vice President and President, Biosciences Division at Emergent BioSolutions, overseeing all areas involving product development, manufacturing and commercialization. He also served as Vice President of 3M Pharmaceuticals.
Dr. Karen Cheng Joins Fishawack Archimed Drug Safety Experts
Fishawack Archimed AG, a UK-based company that specializes in providing drug safety and regulatory communications including pharmacovigilance support for leading pharmaceutical, biotechnology and medical device companies, appointed Dr. Karen Cheng, MB, ChB FFPM as Senior Drug Safety Director. Having worked for nearly 10 years as Risk Management Physician and Global Safety Physician at Boehringer Ingelheim and AstraZeneca in Germany and the UK, respectively, the doctor brings valuable expertise to the company.
“I’m passionate about pharmacovigilance, and am looking forward to partnering with Fishawack Archimed’s clients to help optimize this key patient-centric area with them,” says Dr. Cheng.
Alzheon
Appointed Jean-Pierre Garnier, PhD as Chairman of its Board of Directors to apply his expertise and transform the company into a leading clinical-stage Alzheimer’s company. Garnier is highly respected for his world-class expertise and global perspective.
Chase Pharmaceuticals
A clinical-stage biopharmaceutical company focused on treatments for neurodegenerative disorders including Alzheimer’s disease, named Douglas S. Ingram Chief Executive Officer and a member of the company’s Board of Directors. Ingram has earned accolades during his previous tenure as President of Allergan until its acquisition by Actavis. He has almost 20 years of biotech, pharmaceutical and medical device experience.
Chiasma
A late-stage biopharmaceutical company, focused on orphan disease acromegaly, appointed John F. Thero to its Board of Directors. He will serve as chairman of the audit committee. Thero has more than 20 years of financial and operational managing experience. He has 15 years experience growing life sciences companies including Amarin. Chiasma also named James R. Tobin as a member of its Board of Directors. He will serve as a member of the audit committee. Tobin previously served as President and CEO of Biogen, Inc. and Boston Scientific Corporation.
CRISPR Therapeutics
A company focused on the development of transformative gene-based medicines, appointed Dr. Tony Coles to its Board of Directors. Dr. Coles is the founding investor of Yumanity Therapeutics where he also serves as Chairman and Chief Executive.
FORUM Pharmaceuticals
Named human resources veteran, George Parker as Chief Human Resources Officer. With more than 25 years experience in the field, he is entrusted with all aspects of the company’s human resources matters. FORUM Pharmaceuticals is a biopharmaceutical company focused on transformative medicines to treat brain diseases.
Kalytera Therapeutics
Announced the addition of Dr. Jerome Zeldis to its Board of Directors. Dr. Zeldis also works with Celgene Corporation where he serves as Chief Medical Officer. Kalytera is focused on developing a portfolio of non-psychoactive cannabinoid (CBD) and synthetic CBD medicines.
Merz North America
Named Philippe Adams Vice President, Managed Markets. His responsibilities include developing the company’s market access and reimbursement strategy with the goal of enhancing patient access to Merz prescription products. Adams has more than 20 years experience in the pharmaceutical and medical device industry.
Momenta
Appointed Matthew P. Ottmer as COO to lead the operational management of strategic product development, pharmaceutical sciences and commercial activities. Formerly, he served as Senior Vice President, Strategy & Emerging Businesses at Biogen. Ottmer’s experience will advance the company’s biosimilar and novel drug programs toward commercialization.
MonoSol Rx
Welcomed financial and operational expert Joanne M. Leonard as its Chief Financial Officer. Leonard has 25 years experience in the field. As the former COO of Epigenesis Pharmaceuticals, she secured the company’s first private placement with venture capital, earning recognition as a finalist for the NJ Technology Counsel CFO Deal of the Year Award.
OncBioMune Pharmaceuticals
Appointed Charles L. Rice, Jr. to its Board of Directors, anticipating that his legal, management, leadership and budgeting skills will be a great contribution to the company. Rice was the Chief Administrative Officer for the City of New Orleans, responsible for 6,000 employees and a $600 million budget.
Pulmatrix
A company concentrated on inhaled therapies for pulmonary disease welcomed Mark Iwicki as Chairman of its Board of Directors. Iwicki is considered a pharmaceutical industry leader, with 25 years experience managing all stages of drug development.
Rock Creek Pharmaceuticals
Recruited Christopher Griffiths, MD, FMedSci, Foundation Professor of Dermatology at the University of Manchester and an honorary consultant at Salford Royal NHS Foundation Trust as a Key Opinion Leader, along with Vincent Piguet, MD, PhD, FRCP, Professor and Head of Department of Dermatology & Wound Healing and Director of the Division of Infection & Immunology at Cardiff University and the University Hospital of Cardiff, Wales.
